Mesoblast Limited (MEOBF)
| Previous Close | 0.7600 |
| Open | 0.7600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.7600 - 0.7600 |
| 52 Week Range | 0.1000 - 1.0000 |
| Volume | |
| Avg. Volume | 90,027 |
| Market Cap | 866.94M |
| Beta (5Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
As the Australian market navigates through fluctuating bond yields and anticipates potential interest rate hikes, investors are closely monitoring various economic indicators and corporate activities. Amid these conditions, companies with high insider ownership can be particularly intriguing, as such ownership might align management's interests more closely with those of shareholders, potentially fostering greater resilience and long-term strategic focus during uncertain times.
- Zacks
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
- Insider Monkey
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript February 29, 2024 Mesoblast Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Silviu Itescu: Good morning, good afternoon to Mesoblast’s Financial Results and Operational Update for the Half Year ended December 31, […]
